<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01787656</url>
  </required_header>
  <id_info>
    <org_study_id>USA-MCI GON-1.01</org_study_id>
    <nct_id>NCT01787656</nct_id>
  </id_info>
  <brief_title>A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus</brief_title>
  <official_title>A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Alabama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ProHealth Care, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Women's Cancer Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tennessee Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arizona Oncology Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sarasota Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Florida Hospital Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Crescent City Physicians, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanford USD Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monongalia General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sacred Heart Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tennessee Valley Gynecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tulane University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Center of South Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marshall University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Luke's Hospital and Health Network, Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mercy Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Alabama</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ovarian cancer is deadly and generally diagnosed at late stage when the chances of survival&#xD;
      are low. There is a current belief that this cancer starts in the fallopian tubes and&#xD;
      progresses towards the ovaries, spreading to the cells on the surface. Within the fallopian&#xD;
      tubes and the uterus, there is a constant flow of mucus which has only one exit through the&#xD;
      cervix and out the vagina. Proteins that are generated within the entire female reproductive&#xD;
      system are trapped into this viscous fluid and eventually released as waste. When a routine&#xD;
      PAP test is performed, a sample of this mucus is collected along with any cells, and&#xD;
      preserved in the PAP fluid. The fluid is currently discarded but contains a protein profile&#xD;
      showing of the status of the cells in the female reproductive system. We have examined this&#xD;
      fluid and found that it contains unique peptides/proteins that provide a diagnosis of ovarian&#xD;
      cancer when compared against healthy controls. These markers will be initially refined using&#xD;
      the comparison of ovarian cancer patients against those with benign adnexal masses that&#xD;
      entered the clinic during the same time period.&#xD;
&#xD;
      In this Phase II biomarker validation study we will further refine and validate these&#xD;
      biomarkers using a new collection of samples from at least 200 ovarian cancer cases with&#xD;
      epithelial ovarian cancer (endometroid and papillary serous histology, most common) and&#xD;
      comparing these against 600 patients with a diagnosis of a benign adnexal mass that enter the&#xD;
      clinics during the same time period. Patient samples will be collected on their first visit&#xD;
      to the gynecologic oncologist at a number of collaborating clinics. Final processing of all&#xD;
      of the samples will be performed within the proteomics research facilities of the Mitchell&#xD;
      Cancer Institute using Selected Reaction Monitoring (SRM, with mass spectrometry) based on&#xD;
      the refined set of makers statistically selected within the first aim. Biomarkers validated&#xD;
      within this study will be compared with the well accepted CA-125 data for the patients. The&#xD;
      research involves a three year validation and may allow detection of this cancer at a very&#xD;
      early stage when the survival is as high as 90%. One aim examines a self-taken test that&#xD;
      could allow its use in medically underrepresented and rural areas.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Discovery of biomarkers that allow for the early detection of ovarian cancer</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">438</enrollment>
  <condition>Ovarian Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      De-idetified samples of gynecologic fluid, mucus, and blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with an adenxal mass or suspicion of ovarian, fallopian tube, or primary peritoneal&#xD;
        cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be fully consented to the collection of the samples in writing (completed consent&#xD;
             forms).&#xD;
&#xD;
          2. Age Criteria: Women age 50 and older who are post menopausal (defined as 12 months&#xD;
             past last menstrual period).&#xD;
&#xD;
          3. Must have: Diagnosis of an adnexal mass or a suspicion of ovarian cancer, or a&#xD;
             suspected fallopian tube or primary peritoneal cancer.&#xD;
&#xD;
          4. Must have a uterus and cervix.&#xD;
&#xD;
          5. Surgery for the adnexal mass must be anticipated. (Only patients with an adnexal mass&#xD;
             requiring surgery will be eligible).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any subject who has a condition that would increase the risk associated with the&#xD;
             standard sampling procedures (Such as a pap smear, or cotton swab in vagina)&#xD;
&#xD;
          2. Prior hysterectomy.&#xD;
&#xD;
          3. Absence of adnexal mass.&#xD;
&#xD;
          4. Primary diagnosis of a cancer other than ovarian, primary peritoneal or fallopian&#xD;
             tube.&#xD;
&#xD;
          5. Patients with grossly visible cervical cancer.&#xD;
&#xD;
          6. Previous/recent treatment for any invasive gynecologic cancer.&#xD;
&#xD;
          7. Recent chemotherapy within the prior 2 years. (recent neoadjuvant chemotherapy for&#xD;
             ovarian cancer would exclude the patient from participation).&#xD;
&#xD;
          8. Cervical conization within the prior 6 months.&#xD;
&#xD;
          9. History of Radiation therapy to the pelvis, vagina or cervix.&#xD;
&#xD;
         10. Obvious advanced stage cancer (Stage III or IV) on presentation, if known prior to&#xD;
             specimen collection.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Finan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Alabama</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 6, 2013</study_first_submitted>
  <study_first_submitted_qc>February 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2013</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

